• Peripheral nerve injury can cause low-grade neuroinflammation.
Introduction: the clinical problem of persistent pain after surgery
Acute pain in response to injury is an important mechanism that serves to protect living beings from harm. The pain signals transmitted from the site of injury to the brain cause us to avoid harmful, noxious stimuli. However, severe pain that is sustained for a long time after the injury has healed serves no useful purpose and is a disabling condition. Persistent pain is devastating for individuals and causes substantial health impairment and significant social, financial, and work-related difficulties [1] [2] [3] . From a social point of view, persistent pain is a large burden and results in the use of extensive resources for sick leave, disability retirement, and rehabilitation.
Persistent postsurgical pain, which is often defined as pain that remains for 3 months or more after surgery, is the second most common cause of chronic pain after degenerative disease [4] . Recent reports regarding persistent postsurgical pain confirm that it is a complex and highly significant clinical problem [5] [6] [7] [8] . A study that included 2043 patients [9] demonstrated that 12% of patients who underwent an elective, mixed type of surgery developed moderate persistent postsurgical pain and 7% developed severe persistent postsurgical pain. Persistent postsurgical pain after a number of surgical procedures has been described, the prevalence of persistent postsurgical pain varies with the type of surgery, ranging from 50% for limb amputation, 30% for breast surgery, and 10% for hernia repair [5, 10, 11 ].
Neuropathic pain conditions in persistent postsurgical pain (PPP)
Persistent postsurgical pain is strongly associated with neuropathic pain [12, 13] . Depending on the type of surgery, neuropathic pain is experienced by 3% (laparoscopic surgery) to 68% (breast surgery) of patients with persistent postsurgical pain. Neuropathic pain is characterised by lesion to or disease of the somatosensory nervous system [14, 15] . It is recognised by pain that is distributed and localised along the innervation territory of the affected nerve, and it is always accompanied by a sensory disturbance, such as hyperesthesia or hypoesthesia, in the affected area. When established, neuropathic pain is difficult to treat, and conventional pain therapy is often insufficient.
It seems that nerve damage is a prerequisite for the development of neuropathic pain. However, nerve damage does not always produce neuropathic pain [13, 16] .
Possible mechanisms for the transition from acute physiological pain to persistent pain that remains after an acute injury has healed include nerve injury followed by inflammation in the peripheral nervous system (PNS) and CNS [17, 18] .
Objectives of this review
This review will focus on neuroinflammation and subsequent glial dysfunction [19] as possible contributors to the development of persistent postsurgical neuropathic pain [20] [21] [22] . Other possible mechanisms for persistent pain include long-term potentiation, peripheral as well as central sensitisation, neuronal plasticity, neural ectopic activity and disinhibition [23] [24] [25] . These entities, which all concur with our theory, are not the main focus of this review and therefore, will not be further discussed here.
Methods
Concerning the literature search for this paper a convenient selection of publications from searching PubMed was used. Search words were pain, neuroinflammation, glia, astrocytes, microglia, persistent postsurgical pain, persistent postoperative pain, neuropathic pain, inflammation, morphine, endomorphin, naloxone, levetiracetam and also different combinations of these.
Peripheral injuries can cause low-grade neuroinflammation
When an injury occurs in peripheral tissue, pro-inflammatory mediators, such as nitric oxide, bradykinin, tissue factors, and prostaglandins, are released into the bloodstream, and white blood cells are attracted to the injury site. The endothelium that lines the blood vessels becomes permeable, and leucocytes migrate from the blood vessels to the injury site [26] . A peripheral inflammatory process can also induce low-grade inflammation in the CNS; this process is known as neuroinflammation [27, 28] .
Blood-brain barrier made permeable by cytokines
After a peripheral nerve injury, inflammatory activated leucocytes release pro-inflammatory cytokines [29] . These cytokines cause the blood-brain barrier (BBB) to become permeable, thereby allowing leucocytes to migrate through and transform into microglia in the CNS [30] [31] [32] [33] . The activated microglia produce more pro-inflammatory cytokines, such as IL-1␤ and TNF-␣. In turn, IL-1␤ activates astrocytes, which also release the pro-inflammatory cytokine IL-1␤. This combined response causes a change in the astrocyte network signalling, thus potentiating neuronal pain transmission [34] [35] [36] [37] . Furthermore, this reaction is associated with the development of new synapses and dysfunction of existing synapses [38] [39] [40] [41] [42] [43] .
Neuroinflammation can also be initiated when a local peripheral injury produces inflammatory activation in the CNS [44] , which is conveyed by neurogenic sites of action. Macrophages infiltrate the injured nerve [45] and cause an inflammatory reaction in the nerve cells.
Microglia and astrocytes' function are altered by neuroinflammation
This reaction leads to microglia activation in the CNS and the release of pro-inflammatory cytokines that activate and alter astrocyte function [46, 47] .
Microglia and astrocytes are non-excitable neural cells that play an active role in the development of neuroinflammation [48] [49] [50] [51] . In the last few years, it has become clear that glial cells have important metabolic and immune functions [52] and may play an important role in the modulation of synaptic pain transmission [53, 54] . Astrocytes and microglia are glial cells that surround, support, and interact with neurons in the CNS. They respond to inflammatory stimuli and may play an important role in modulating the inflammatory activity in the CNS, as observed after peripheral injuries [55] . Astrocytes are coupled in networks and communicate with each other and with neurons [56, 57] thereby modulating neuronal activity [58] . Inflammation causes dysfunction in glial-neuron communication due to inflammatory-induced alterations in astrocyte function that disturb the two-way interaction between astrocytes and neurons. This disturbance results in increased excitability in neurons, and synaptic pain transmission is enhanced and prolonged [59, 60] .
Microglia and astrocytes' important role in development of neuropathic pain
The CNS consists of neurons and glial cells; the latter account for 70% of the cells. Microglia and astrocytes are important for the development of persistent pain [61] . Additionally, dorsal root ganglion satellite cells, which are astrocyte-like cells in the PNS, may play a role in the development of neuropathic pain [53] . However, they will not be discussed further in this review.
Microglia initiates neuroinflammation
Microglia are resident macrophages in the CNS, and they rapidly respond to an injury by proliferating, changing shape and producing pro-inflammatory cytokines [25] . Within 2 days of a peripheral nerve injury, there is marked proliferation of microglia in the spinal cord [62] . Hence, microglia are most likely the cell type that initiates inflammation in the CNS, thereby leading to further activation and spread of inflammation by the astrocytes [46] .
Astrocytes can modify neuronal activity
Astrocytes are the most abundant cells in the CNS. They are starshaped cells with long, slender processes. Astrocytes are coupled by gap junctions in syncytial networks and occupy a strategic position between the vasculature and the neurons, where they monitor and modify neuronal activity and transmitter release [59] . Astrocytes can release a rich variety of neuroactive substances, and they also express receptors for these substances. They surround neural synapses with their end-feet and monitor and modulate synaptic activity. One astrocyte can contact approximately 100,000 synapses [63, 64] , which makes their impact on synaptic transmission significant.
Astrocytic calcium (Ca 2+ ) signalling
Astrocytes display a form of excitability that manifests as an increased intracellular Ca 2+ concentration. Stimuli, such as transmitters released from neurons and glial cells, can evoke Ca 2+ elevation in single astrocytes, which passes to adjacent astrocytes and leads to a Ca 2+ wave that can propagate over long distances [65] [66] [67] . 
Gap junction coupling
For this machinery to function, intercellular channels that are referred to as gap junctions appear to be necessary [68] . These channels enable direct exchange of ions, metabolites, and small molecules (less than 1.5 kDa in size) between contiguous cells [69] . Connexin 43 (Cx43) is the primary gap junction protein [70] . Astrocytes in most parts of the CNS use two types of Ca 2+ communication: intercellular communication through gap junctions and extracellular communication through diffusion of adenosine triphosphate (ATP), which then binds to purinoceptors on adjacent cells [70] .
Glutamate-glutamine cycle
One of the roles of astrocytes is to clear the synaptic cleft of glutamate released from the neurons, thereby preventing neurotoxicity due to excessive amounts of glutamate [71, 72] . Neuronal activity releases glutamate into the neural synapse. The glutamate is taken up by astrocytes and converted to glutamine by the enzyme glutamine synthetase. Glutamine is released back into the synaptic cleft, taken up by neurons, and metabolised to glutamate, which is again released into the synaptic cleft; this process is referred to as the glutamate-glutamine cycle [73, 74] .
The inflammatory activated astrocytes cannot sufficiently clear the synaptic cleft of glutamate. Glutamate is an excitatory neurotransmitter, and the increased glutamate level in the synaptic cleft makes the neurons more excitable [75] .
Astrocytic cellular dysfunction in inflammatory conditions
Cellular changes that occur during neuroinflammation render the astrocyte networks unable to interact appropriately with neurons, thereby altering synaptic transmission (Figs. 1 and 2 ). During inflammation, the expression and affinities of several receptors are changed. 
Toll like receptor-4 is a pro-inflammatory receptor
In astrocytes, Toll-like receptor 4 (TLR4) is an inflammatory receptor that responds to lipopolysaccharide (LPS) by increasing its expression and activity [76, 77] . Activation of TLR4 leads to an increase in the release of the pro-inflammatory cytokines TNF-␣ and IL-1␤ [78] . Activation of TLR4 can be inhibited by ultralow doses of naloxone [79] and interestingly, it can be increased by prolonged morphine administration [80] .
Astrocytes communicate with Ca 2+ waves
Astrocytes communicate and modulate synaptic activity through Ca 2+ waves. Release of Ca 2+ can be stimulated by substances released from both neurons and glial cells [81, 82] . Receptors on the surface of astrocytes are coupled to G proteins and release Ca 2+ from the endoplasmic reticulum via phospholipase C and inositol-triphosphate (IP 3 ) [83] . These Ca 2+ waves can propagate from one cell to another via gap junctions. An increase in cytosolic Ca 2+ leads to release of gliotransmitters, i.e., substances that can influence and modulate synaptic transmission [68] . Prolonged neuroinflammation causes dysfunction of this signalling system [84, 85] .
Na + /K + ATPase modulates Ca 2+ signalling
Influx of Ca 2+ across the plasma membrane is driven by the Na + electrochemical gradient across the plasma membrane and the Na + pump, Na + /K + -ATPase, which indirectly modulates Ca 2+ signalling [86] . Inflammatory stimuli disturb the Ca 2+ homeostasis in astrocyte networks, possibly by interfering with the activity of Na + /K + -ATPase [86] .
An intact cytoskeleton is needed for Ca 2+ signalling
Na + /K + -ATPase, the actin filaments that constitute the cytoskeleton, and the endoplasmic reticulum are associated through the adaptor protein ankyrin B [87] . Na + /K + -ATPase is connected to the actin filaments by the protein ankyrin B, and the actin filaments are connected to the endoplasmic reticulum by the same protein. If the actin filaments are disrupted, the Ca 2+ release is disturbed. An intact cytoskeleton is required for propagation of Ca 2+ waves in astrocytes, and disruption of the cytoskeleton abolishes Ca 2+ waves by changing the balance among the Ca 2+ -regulating processes [88] . In inflammatory states, the cytoskeleton is disrupted.
Pro-inflammatory cytokine IL-1ˇ closes gap junctions
In the CNS, IL-1␤ is mainly produced by microglia that are active in initiating the inflammatory process, whereas astrocytes, which also produce significant amounts of IL-1␤, are dominant in maintaining neuroinflammation [89] . The increase in IL-1␤ closes the gap junctions, thereby inhibiting the normal propagation of Ca 2+ waves through the astrocytic networks [90].
Inflammation disrupts astrocytes' communication
In inflammatory states, the increase in pro-inflammatory cytokines leads to increased production of ATP. These changes disturb the normal Ca 2+ signalling [91] , which can result in Ca 2+ oscillations. Gap junctions close because of high levels of IL-1␤, and the intercellular Ca 2+ waves and propagation from cell to cell are attenuated [92] . The increased extracellular release of ATP acts on purinergic receptors on adjacent astrocytes, consequently stimulating the release of intracellular Ca 2+ in adjacent cells [93] . This stimulation leads to poorly controlled extracellular propagation of the Ca 2+ waves, and the increased intracellular Ca 2+ release exhibits oscillatory behaviour [70] (Fig. 2) . Fig. 3) The cellular changes that occur during experimental neuroinflammation render the astrocyte network unable to interact appropriately with neurons and synaptic transmission [94] . To restore the cellular changes caused by the experimental neuroinflammation described above, we searched the literature for substances with possible anti-inflammatory properties that are usually used for other purposes in medicine.
Reversing glial dysfunction (
6.1. Endomorphin-1 stimulates the -opioid receptor and Na + /K + ATPase Endomorphin-1 (EM-1) is a peptide and an endogenousopioid receptor agonist [95] [96] [97] . EM-1 is released from nerve endings into the general circulation [98] . It has also been found in inflammatory tissue, implying that it may interact with immune cells. Astrocytes possess -opioid receptors, and endomorphins may play a role in the control of neuroinflammatory activity [99, 100] . Morphine activates the -opioid receptor, which in turn activates the second messenger protein G i/o . The complex ofopioid receptor and G i/o works by multiple mechanisms to inhibit neural pain impulses, thereby decreasing pain sensations in the brain [101, 102] . EM-1 and morphine have been shown to stimulate Na + /K + -ATPase activity in vitro [103] . 
Naloxone inhibits the excitatory second messenger protein G s and restores actin filaments
Naloxone is an effective -opioid receptor antagonist when used at higher doses (mg), and it is widely used in clinical practice to reverse opioid overdoses [104] .
At ultralow doses (pg) the mechanism of naloxone is different. In states of low-grade neuroinflammation, such as chronic pain states [31, 105] , and even after long-term morphine treatment [106, 107] the -opioid receptor shifts its coupling from the inhibitory G i/o protein to the excitatory G s protein [108, 109] . This switch causes diminished pain relief and increased morphine tolerance. Naloxone at ultralow concentrations has the ability to block -opioid receptor-coupling to the excitatory G s protein and causes theopioid receptor to couple to the inhibitory G i/o protein [110, 111] . Naloxone can also restore to some extent, inflammatory disrupted actin filaments [77] .
Levetiracetam opens blocked gap junctions
Levetiracetam is an effective anti-epileptic drug. Levetiracetam inhibits the neural release of transmitters into the synaptic cleft by binding to a protein that regulates exocytosis [112, 113] . In our experimental work, levetiracetam was used for its antiinflammatory properties. Levetiracetam has been shown, in inflammation-reactive astrocyte models, to restore functional gap junction coupling [114] by increasing the expression of connexin 43, the predominant gap junction protein, and decreasing the enhanced IL-1␤ level [115] . 
Experimental studies of the combination endomorphin-1, naloxone and levetiracetam
The combination of the endogenous -opioid agonist endomorphin-1, the -opioid antagonist naloxone at ultralow concentrations and the anti-epileptic drug levetiracetam yielded promising results as regards restoration of cellular changes caused by experimentally induced inflammation [94] .
During inflammation, the -opioid receptor switches its normal activation target from the G i/o protein to the G s protein [110, 111, 116] . At ultralow doses, naloxone blocks G s and forces G i/o activation, which promotes normal endomorphin-1-induced Ca 2+ release [117] . Second, the addition of levetiracetam in combination with endomorphin-1 and ultralow doses of naloxone restored the actin filaments, attenuated the release of IL-1␤ and unblocked the gap junctions, thus enabling restoration of Ca 2+ signalling (Fig. 3) . Experimentally, a combination of endomorphin-1, ultralow doses of naloxone and levetiracetam can attenuate inflammatoryinduced astrocytic changes and restore intercellular Ca 2+ signalling. It is possible that this type of action influences the intercellular communication between astrocytes and exerts effects on synaptic pain transmission in neurons. Nevertheless, there is a large difference between results produced in a laboratory using cellular cultures and outcomes in a clinical setting. Thus, these results need to be assessed in a clinical setting.
Clinical applications
Our group performed a pilot study consisting of eleven patients with persistent pain following multiple surgeries, who were being treated with continuous intrathecal morphine administration; in the study, ultralow-dose naloxone was administered via the same route [118] . The reason for not using the above discussed triple combination is that we wanted the option to investigate the effect of each agent individually in vivo.
Two dosages of naloxone were used: 40 ng/24 h and 400 ng/24 h. Neither of these interventions was associated with statistically significant changes in pain status, as assessed with the Numeric Rating Scale (NRS) (Fig. 4) . Nevertheless, three study patients who did not improve with placebo experienced marked pain relief with one of the doses of adjuvant intrathecal naloxone.
An unexpected finding was that adjuvant naloxone 40 ng/24 h significantly improved the perceived quality of sleep compared with the placebo (Fig. 5) [118] .
The underlying mechanisms of the clinical findings are complex. In healthy states, morphine stimulates the -opioid receptor, which in turn stimulates the inhibitory G i/o protein; however, in states of low-grade inflammation, this coupling decreases, and the coupling of the -opioid receptor to the excitatory G s protein increases [119] [120] [121] . As described above, using cellular cultures, it has been demonstrated that ultralow doses of naloxone can inhibit the G s protein, and the -opioid receptor coupling to the G i/o protein subsequently increases [122] .
Conclusions
Peripheral nerve injury can cause low-grade inflammation in the CNS known as neuroinflammation. Low-grade neuroinflammation can cause an imbalance in the glial-neuron interaction and communication.
Experimentally induced inflammation causes changes in astrocyte function. The expression of the inflammatory receptor TLR4 is increased, the Ca 2+ wave signalling is changed, the expression of Na + /K + -ATPase is decreased, the actin filaments are disorganised, and the release of IL-1␤ is increased. These changes cause an imbalance in the astrocyte-neuron interaction that renders the neurons overly excitable, which produces enhanced and prolonged pain signalling.
The disturbed signalling can be restored in vitro by treating astrocytes with a combination of endomorphin-1, and ultralow doses of naloxone and levetiracetam. Ultralow doses of naloxone block the excitatory G s protein. Subsequently, the action of endomorphin-1 on the inhibitory G i/o protein is enhanced. Levetiracetam attenuates the inflammatory-induced release of glial IL-1␤. The combination of endomorphin-1, naloxone, and levetiracetam successfully counteracts the inflammatory-induced cellular changes caused by LPS. This restoration is essential for intercellular astrocyte Ca 2+ communication and the interaction between astrocytes and neurons and hence also for modulation of synaptic pain transmission.
Implications
Surgery or trauma causes inflammation at the site of injury. Nerve injury causes low-grade inflammation in the CNS and PNS. Neuroinflammation that persists after the acute injury has healed may be an important component of establishing persistent postsurgical neuropathic pain. Restoring inflammatory-activated astrocytes, thereby inhibiting enhanced pain transmission in neurons, is a potentially interesting method. Larger studies in clinical settings are needed before the abovementioned findings can be applied in a clinical context. Potentially, by targeting inflammatory activated glial cells and not only neurons, a new arena for development of pharmacological agents for persistent pain is opened.
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